Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

84
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

24
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.5K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.5K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.4K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.4K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.7K
The pathophysiology of pneumonia involves the following steps:
4.7K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.2K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cluster of clonal fluconazole-resistant Candida parapsilosis harbouring Y132F mutation in ERG11 gene in a neonatal ICU in the UK.

The Journal of antimicrobial chemotherapy·2025
Same author

Comment on: In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).

The Journal of antimicrobial chemotherapy·2024
Same author

The impact of immunosuppressive therapy on secondary infections and antimicrobial use in COVID-19 inpatients: a retrospective cohort study.

BMC infectious diseases·2023
Same author

National action plans for antimicrobial resistance and variations in surveillance data platforms.

Bulletin of the World Health Organization·2023
Same author

Multidrug-resistant infections in war victims in Ukraine.

The Lancet. Infectious diseases·2023
Same author

Population Pharmacokinetic Study of Benzylpenicillin in Critically Unwell Adults.

Antibiotics (Basel, Switzerland)·2023
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

14.6K

Atypical pneumonia.

Marina Basarab1, M Bruce Macrae, Carmel M Curtis

  • 1Department of Clinical Microbiology and Virology, University College London Hospital, London, UK.

Current Opinion in Pulmonary Medicine
|March 15, 2014
PubMed
Summary
This summary is machine-generated.

Advances in atypical pneumonia diagnosis and treatment are emerging. Molecular diagnostics are improving, but challenges remain in distinguishing infection from carriage, alongside the rise of macrolide-resistant Mycoplasma pneumoniae.

More Related Videos

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.9K
Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

3.1K

Related Experiment Videos

Last Updated: May 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

14.6K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.9K
Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

3.1K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pulmonology

Background:

  • Atypical pneumonia encompasses infections like legionellosis, Mycoplasma pneumoniae, Chlamydophila species pneumonia, and Q fever.
  • Understanding and diagnosing these infections is crucial for effective patient management.

Purpose of the Study:

  • To review key advances in the diagnosis and management of atypical pneumonia.
  • To highlight recent developments in molecular diagnostics and antimicrobial therapies.

Main Methods:

  • Review of recent literature on atypical pneumonia pathogens.
  • Focus on advancements in molecular diagnostic techniques, such as multiplex PCR.
  • Analysis of emerging antimicrobial resistance patterns and new therapeutic agents.

Main Results:

  • Molecular diagnostics for Mycoplasma pneumoniae and Chlamydophila pneumoniae are advancing with multiplex PCR.
  • Diagnostic challenges persist in differentiating between pathogen carriage and active infection.
  • Emergence of macrolide-resistant Mycoplasma pneumoniae, particularly in Asia, and development of new ketolide antimicrobials.

Conclusions:

  • Limited progress in understanding atypical pathogen epidemiology and antimicrobial therapy effectiveness.
  • Widespread molecular testing implementation is expected to enhance epidemiological insights and promote targeted antimicrobial therapy.
  • New antimicrobial classes offer potential for empirical and pathogen-specific treatment.